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A B S T R A C T
Recurrent small cell lung cancer is a recalcitrant malgnancy. The application of genomic technologies has
begun to elucidate the large number of genetic abnormalities in SCLC. Several cell surface receptors are
known to be overexpressed by SCLC in clinic specimens and cell in culture including GPCRs such as the
bradykinin receptor, the chemokine receptor CXCR4, the vasopression receeptor and the three bomebsin
receptors. The glucose transporter GLUT1, the tetraspanin family member PETA/CD151 and the
immunoglobulin superfamily member ALCAM/CD166 are also overexpressed by SCLC. NCAM/CD56 is
overexpressed by nearly all SCLC and is currently the target for an antibody drug conjugate in Phase II
trial. Although SCLC is not considered a RTK driven disease, IGF1R and FGFRs are often overexpressed by
SCLC. SCLC abberantly expresses several developmental transcription factors including ASCL1, SOX2, 4,
and 11, OCT4, NANOG, PAX5; however, overexpression of MYC may be a driver in SCLC. Like other
cancers, SCLC expresses survival factors and uses aerobic glycolysis as a major source of ATP. The
drawback of many ponteial targets overexpressed by SCLC is expression of the same proteins by normal
tissues. We are slowly learning more about the molecular abnormalities that occur in SCLC; however,
therapeutic impact from new ﬁndings remains a goal to work toward.
Published by Elsevier Inc.
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Small cell lung cancer (SCLC) is an extremely aggressive cancer
that frequently recurs after conventional cytotoxic chemotherapy.
Even in cell culture the differences between SCLC and non-small
lung cancer (NSCLC) are clear. SCLC cells are, indeed, small with
limited cytoplasm surrounding the nuclei. The cells tend to grow as
ﬂoating clusters or spheroids which are often difﬁcult to
disaggregate. NSCLC cells grow as monolayers like most solid
tumor cells. While SCLC is challenging to work with in culture, it
tends to grow well as xenografts. SCLC is a neuroendocrine lung
malignancy for which there is no effective treatment that affects
>200,000 people world-wide every year with a very high mortality
rate. In the United States, SCLC is 13–15% of lung cancer cases.
Although initially a chemotherapy and radiation-sensitive disease,
SCLC recurs rapidly and <5% of patients survive ﬁve years. There
has no change in the standard of care for SCLC over the past three
decades. Treatment most often involves platinum-based combi-
nation chemotherapy, hyperfractionated thoracic radiation, and
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oncogenes, and signaling pathways, upregulation of receptor
tyrosine kinases, growth factors and cellular markers, and active
early development pathways [3].
From 1977 through 1992, 126 SCLC cell lines were established
from patients at the NCI-Navy Medical Oncology Branch. Extensive
clinical information was available on 96 patients from whom these
cell lines were established. These patients comprised approximately
one fourth of the 407 patients treated on prospective therapeutic
clinical trials during the same time period. The proportion of tumor
cell lines established from previously untreated patients with both
limited and extensive stage SCLC increased during the 16 years of the
study. These cell lines became and remain critically important
models for the study of this deadly malignancy [4].
Based upon alterations that occur in SCLC, this review begins at
the SCLC cell surface and progresses through the cell and discusses
potential targets for SCLC treatment.
2. Cell surface
2.1. CD24
The expression of CD24 cancer stem cell-associated membrane
protein, a glycosylphosphatidyl-inositol-anchored molecule in-
volved in cell adhesion, is increased in several tumor types and is
Fig. 1. Schematic depicting potential drug targets in small cell lung cancer (SCLC).
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CD24 is composed of31–35 amino acids, is highlyglycosylated,and is
highly expressed by SCLC, but rarely by NSCLC [5]. To investigate
CD24 expression on radiation sensitivity, sublines of human NCI-
H249 SCLC transfected with mutated ras, and differing in CD24
expression and CD24 transfected NSCLC A125 and NIH3T3 cells, were
studied. CD24 expression had no inﬂuence on cellular morphology,
proliferation or cloning efﬁciency. In radiation studies conducted
withexponentially growing cells, there was nodifference in radiation
response observed between CD24 expressing and non-expressing
NSCLC cells. In the radiosensitive SCLC H249-ras cells, similar
responses to radiation were observed between CD24 expressing and
non-expressing cells, whereas CD24 transfected NIH3T3 mouse
ﬁbroblasts were more radio-resistant than CD24 non-expressing
control cells [6] (Fig. 1).
CD24 increases cell invasion via biomechanical processes that
require cell adhesion to the extracellular matrix through hetero-
dimeric b1-integrin receptors. Integrin localization in lipid rafts
depends on CD24. CD24 negative cells stably transfected with
CD24 were sorted into high and low CD24 expressing subpopula-
tions. CD24 and b1-integrin knockdown in CD24high cells
decreased invasiveness. Invasion assays in the presence of myosin
light chain kinase inhibitor ML-7 or Rho kinase inhibitor Y27632
decreased invasiveness in CD24high cells but not in CD24neg cells.
Lysophosphatidic acid or calyculin A addition enhanced invasive-
ness in CD24neg cells. Src kinase or STAT3 inhibition decreased
invasiveness of CD24high cells, reduced that of CD24low cells, and
did not alter CD24neg cells invasiveness [7].
Hypoxia drives malignant progression in part by promoting
production of HIF1a. Hypoxia induces CD24 expression through a
functional hypoxia responsive element in the CD24 promoter.
Short hairpin RNA-mediated attenuation of HIF1a or CD24
expression reduced cell survival in culture and decreased primary
and metastatic tumor growth. CD24 overexpression in HIF1a-
depleted cancer cells restored cell and tumor growth, whereas
HIF1a overexpression in CD24-depleted cells did not. In clinical
tumor specimens, co-expression of HIF1a and CD24 correlated
with decreased patient survival [8]. HIF1a is an important
regulatory factor for SCLC angiogenesis. To study HIF1a effect
on SCLC angiogenesis NCI-H446 cells were transplanted onto the
chick embryo chorioallantoic membrane (CAM) surface. Angio-
genic gene expression regulated by HIF1a in the NCI-446 tumors
grown on the CAM was determined. HIF1a upregulated the
expression of VEGF-A, TNFAIP6, PDGFC, FN1, MMP28, and MMP14
by 6.8-, 6.7-, 2.3-, 2.3-, 4.4-, and 3-fold, respectively, and increased
glycolytic proteins GLUT1, and GLUT2 by 3-, and 3.7-fold,
respectively. HIF1a may be a potential drug target for SCLC eitherby direct targeting or indirectly by targeting CD24 or other
pathway member [9].
In a classic study, CD24-targeted SWA I I-SPDBdg-ricin A chain
immunotoxin cytotoxicity was evaluated against SCLC lines and 2
SCLC xenografts, a sc xenograft and a sponge-matrix model of
disseminated SCLC cells to mimic residual disease. Tumor
regrowth after the initial response and clonogenic activity in the
sponge-derived cell population were mediated by CD24+ cells,
excluding the selection of CD24-mutants during immunotoxin
therapy [10]. The targeting of cancer stem cells by monoclonal
antibodies offers new options for therapy. Treatment with
monoclonal antibody SWA11 to CD24 retarded tumor growth in
mice. The treatment led to increased tumor inﬁltration by immune
cells suggesting ADCC involvement. SWA11 treatment altered the
intra-tumoral cytokine microenvironment [11]. Doxorubicin was
also conjugated to the monoclonal antibody SWA11. SWA11-DOX
was rapidly internalized into SCLC cells upon binding to cell-
surface CD24 and was highly cytotoxic and more selective than
free doxorubicin [12]. It may be of interest to re-visit CD24 as an
antibody drug conjugate target for SCLC.
2.2. CXCL12/CXCR4
CXCR4 chemokine receptor overexpression along with CXCL12
ligand expression, is involved in tumor development, growth, and
organ-speciﬁc metastasis. CXCL12 acts via interaction with CXCR4
or CXCR7. Factors that determine CXCL12 receptor preference,
intracellular signaling and biological response are important to
CXCL12 axis therapeutic intervention in disease. 5T4 oncofetal
glycoprotein facilitates functional CXCR4 expression leading to
CXCL12-mediated chemotaxis in mouse embryonic cells. In wild
type and 5T4-KO murine embryonic ﬁbroblasts, CXCL12 binding to
CXCR4 activates ERK and AKT pathways. These pathways are non-
functional in 5T4-KO cells exposed to CXCL12. Without 5T4
expression, CXCR7 is up-regulated and is the predominant CXCL12
receptor, activating a distinct signal transduction pathway with
slower kinetics involving EGFR transactivation, eliciting prolifera-
tion. 5T4 expression marks activation CXCR4 rather than CXCR7
[13]. Activated CXCL12/CXCR4 stimulates several key migratory,
proliferative and survival signaling cellular pathways. Immuno-
histochemical analysis of CXCR4 and CXCL12 expression in
extensive SCLC metastatic to kidney indicated that the kidney
harboring SCLC had CXCL12, but not CXCR4 expression. High
expression of both proteins was found in normal kidney. CXCR4
and CXCL12 expression may be affected by the metastatic
microenvironment [14]. CXCL12 is constitutively secreted by
marrow stromal cells and is key for homing hematopoietic cells to
the marrow. RT-PCR and ﬂow cytometry detect CXCR4 mRNA and
CXCR4 cell surface expression in SCLC lines. CXCL12 exposure
elicited CXCR4 endocytosis, MAP kinase activation, and invasion
into extracellular matrix and adhesion to marrow stromal cells by
SCLC cells. SCLC stromal cell adhesion was inhibited by the speciﬁc
CXCR4 antagonist T140, pertussis toxin, anti-VCAM-1, and CS-1
peptide. Although T140 has not undergone clinical trial, plerixafor,
a bicyclam that blocks the binding of CXCL12 to the cellular
receptor CXCR4, has been FDA approved for mobilization of
hematopoietic stem cell from bone marrow [15]. CXCL12 enhanced
SCLC adhesion to immobilized VCAM-1, demonstrating that CXCR4
can induce integrin activation on SCLC. SCLC has a high propensity
for bone marrow involvement, and CXCR4 and a4b1 integrins are
critical in SCLC interaction with bone marrow stromal cells [16].
SCLC patients are almost exclusively smokers. Acute and
repetitive exposure to nicotine, at concentrations found in the
lungs of smokers was examined using N417 SCLC in culture.
Repetitive nicotine exposure induced activation of the CXCR4/
CXCL12 axis leading to neuronal-like appearance in N417 cells
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chemoresistance, as well as enhanced migration through collagen
matrices and adhesion to and transmigration across lymphatic
endothelial cell monolayers. SCLC differentiation reverted after
cessation of nicotine exposure. Nicotine-differentiated N417 cells
produced bigger and more vascularized tumors in mice, with lower
apoptotic rates, than their non-nicotine exposed counterparts.
CXCL12/CXCR4 is a potential anticancer target for nicotine-
associated SCLC [17].
SCLC adhesion to extracellular matrix or tumor microenviron-
ment stromal cells confers resistance to chemotherapy via integrin
signaling leading to residual disease and relapse. CXCL12-induced
integrin activation resulted in increased SCLC adhesion to
ﬁbronectin and collagen. Stromal cells protected SCLC from
chemotherapy-induced apoptosis; this protection could be antag-
onized by CXCR4 inhibitors. Integrin and CXCR4 activation co-
operate in mediating adhesion and survival signals from the tumor
microenvironment to SCLC. CXCR4 antagonists in combination
with cytotoxic drugs are being explored in SCLC [18]. A cyclic
CXCR4 ligand imaging probe was evaluated in proof-of-concept
studies. Biodistribution, dynamic PET, metabolic stability and
plasma protein binding studies were performed in nude mice
bearing metastasizing OH1 SCLC xenografts. CXCR4 expression on
OH1 tumors was determined by immunohistochemical staining.
68Ga-CPCR4-2 had low uptake in non-tumor tissue and low kidney
accumulation, leading to high-contrast delineation of tumors in
small-animal PET studies. The cyclic peptide CPCR4-2 labeled with
68Ga is a suitable tracer for targeting and imaging of human CXCR4
expression. The high afﬁnity for CXCR4, in vivo stability, and the
excellent pharmacokinetics supports evaluation of 68Ga-CPCR4-2
in proof-of-concept human studies [19]. TF14016, a small peptidic
CXCR4 inhibitor, was assessed in SCLC. Treatment of mice with
TF14016 suppressed pulmonary metastases of CXCR4-expressing
SCLC in size and number. Histological examination showed that
VEGF and CD31-positive microvessels in metastatic foci were
reduced in TF14016-treated mice. CXCR4 may be a target for SCLC
anti-metastatic and anti-angiogenic therapy [20].
2.3. Bombesin receptors
Bombesin and bombesin receptors have a role in SCLC. The
gastrin-releasing peptide (GRP) receptor, neuromedin B (NMB),
bombesin receptors BB3 and BB4 are bombesin receptor subtypes
expressed by tumors. Human tumors (161) were examined for
their bombesin receptor subtype expression using autoradiogra-
phy with a bombesin radioligand in displacement experiments
with unlabeled GRP, bombesin, and NMB. While prostate and
breast cancers, and gastrinomas expressed predominantly GRP
receptors, and intestinal, bronchial, and thymic carcinoids had
NMB receptors, bronchial carcinoids, a large cell neuroendocrine
NSCLC, and SCLC had NMB, BB3 and GRP receptors [21]. BB3 is an
orphan G protein-coupled receptor with sequence homologies to
GRP and NMB receptors which share about 50% amino acid
identity. Using a synthetic BB3 receptor agonist the effect of BB3
activation on adhesion of the SCLC NCI-N417 cells that endoge-
nously express BB3was examined. The BB3 agonist stimulated NCI-
N417 cell adhesion to laminin which stimulates focal adhesion
formation. BB3 may be involved in SCLC invasion and metastasis
[22]. GRP and NMB are regulatory neuropeptides involved in
normal processes, and are implicated as autocrine and/or paracrine
lung cancer growth factors. The signal transduction pathway for
GRP and NMB receptors involves release of intracellular calcium,
and activation of protein kinase C. While all three bombesin
receptors are activated by bombesin agonists, the GRP, NMB, and
BB3 receptors have very different afﬁnities for the mammalian
bombesin-like peptides GRP and NMB, and for bombesin receptorantagonists. A therapeutic strategy based on modulation of
bombesin growth responses would need to take into account
the pharmacologic heterogeneity of the relevant receptors [23].
2.4. Bradykinin receptor
Bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) is an im-
portant SCLC growth factor. The bradykinin antagonist dimer
CU201 acts as a ‘‘biased agonist’’ for neuropeptides by altering Gq
protein signaling. Exposure to CU201 increased SCLC growth
inhibition in combination with doxorubicin, etoposide, cisplatin,
vinorelbine, and paclitaxel in culture. In mice given a CU201
intravenous bolus infusion of 5 mg/kg, the Cmax was 5773 ng/ml
(5uM). CU201 (5 mg/kg/day) inhibited the growth of SCLC
xenografts by subcutaneous or intraperitoneal injection [24].
When bradykinin analog B9430 (DArg-Arg-Pro-Hyp-Gly-Igl-
Ser-DIgl-Oic-Arg) is dimerized by N-terminal crosslinking, the
product B9870 is a potent SCLC growth inhibitor, in culture and in
xenografts. Daily intraperitoneal injection at 5 mg/kg/day begin-
ning on day 8 after SCLC SHP-77 cell implantation gave 65% tumor
growth inhibition. BKM-570 (F5C-OC2Y-Atmp) administered by
intraperitoneal injection at 5 mg/kg/day, produced 90% suppres-
sion of SHP-77 xenograft growth [25]. Some aspects of ligand–B2
receptor interaction in SHP-77 cells were characterized by
measuring the rate at which cells acidify the environment in
response to ligand–receptor binding. SHP-77 cells maximally
acidiﬁed the environment within 30 s after the exposure to
bradykinin or the BK agonist, B9972, with the maximum effect
seen at 1 mM concentration. BK agonists and antagonists differ in
their interactions with the B2 receptor and consequently elicit
different cell responses [26].
2.5. Vasopressin and oxytocin
The vasopressin (VP) gene is mainly expressed in hypothalamic
neurons, where the pro-VP protein is enzymatically cleaved into
peptide hormone components, the neuropeptide VP, VP-associated
neurophysin, and VP-associated glycopeptide. SCLC expresses the
VP gene, however, SCLC pro-VP protein can remain intact and
localize to the cell surface. Polyclonal antibodies directed toward
pro-VP protein, also called neurophysin related cell surface
antigen, bind to SCLC cell surface. A monoclonal antibody
designated MAG-1, selected using a peptide from the VP-
associated glycopeptide COOH-terminal sequence, recognizes
pro-VP protein in SCLC lysates by Western blot. Immunohisto-
chemical analysis found that MAG-1 reacts with human SCLC, but
not with normal pulmonary epithelial cells [27].
The oxytocin (OT) and VP genes, normally transcriptionally
restricted, are activated in SCLC, concomitantly with expression of
their receptors. Intracellular signaling by OT and VP binding to
their speciﬁc receptors was characterized in SCLC. SCLC stimula-
tion led to an increased ERK 1/2 phosphorylation and the
subsequent p90 ribosomal S6 kinase phosphorylation. PLC, Ca2+,
PKC and ERK1/2 were required for OT- and VP-stimulated SCLC
growth. OT- and VP-induced mitogenic effects on SCLC are
mediated by OTR and V1aR signaling [28]. OT- and VP-induced
mitogenic effects were studied in normal human lung tissue, SCLC
and NSCLC. In normal human lung, OTR co-localized with lung
vascular endothelial cells and is not expressed by epithelial lung
cells. SCLC biopsies analyzed expressed OTR (86%) and 71%
expressed OTR, V1aR and V2R. Comparatively, 50% of NSCLC
biopsies tested expressed OTR and 32% expressed OTR, V1aR and
V2R. V1bR/V3R was expressed by 28% of SCLC and 18% of NSCLC. In
SCLC, V1bR/V3R expression correlates with expression of other
neurohypophysial peptide receptors. Neurohypophysial peptide
antagonists may be potential therapeutics for treating SCLC
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adverse events would be necessary [29].
2.6. ALCAM/CD166
ALCAM/CD166, a member of the immunoglobulin superfamily
with ﬁve extracellular immunoglobulin-like domains, promotes
heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) cell–
cell interactions. The I/F8 scFv to ALCAM/CD166 was selected from
a phage display library of human V-gene segments. I/F8 scFv
abolished binding of ALCAM/Fc and CD6/Fc soluble ligands, but did
not compete with the anti-ALCAM/CD166 murine monoclonal
antibodies J4-81 and 3A6 for binding to ALCAM/CD166 expressed
on the surface of SCLC N592 cells. Engagement through I/F8 scFv,
3A6 monoclonal antibody or CD6/Fc ligand induced ALCAM/CD166
internalization which delivered an I/F8 scFv-saporin immunotoxin
into tumor cells expressing ALCAM/CD166 [30]. Screening a phage-
display single-chain antibody library led to the antibody, scFv173,
that recognizes ALCAM, CD166. ALCAM immunohistochemical
staining was positive in frozen human tumor sections and negative
in 9/10 normal human tissues. By ﬂow cytometry, there was
binding to 22/26 cancer lines and no binding to normal blood or
bone marrow cells. Antibody binding inhibited MDA-MB-231 cell
invasion in a Matrigel-coated membrane invasion assay. HCT116
tumor growth was decreased upon exposure to scFv173 compared
to control. Antibodies and antibody fragments recognizing ALCAM
reduced cancer cell invasion, tumor growth and are useful for drug
and imaging agent delivery to cancer cells [31].
2.7. PETA-3/CD151
Among the 33 human tetraspanin proteins, CD151, CD9 and
Tspan12 are important in cancer. Tetraspanin CD151, along with
integrins a6b1 and a6b4, modulates tumor cell growth, invasion,
migration, metastasis, signaling, and drug sensitivity. The 50-6
antibody was generated by subtractive immunization, and
sequence analysis identiﬁed the antigen of mAb 50-6 as PETA-3/
CD151. Inhibition of metastasis by the mAb 50-6 was due to
inhibition of an early step in metastatic foci formation [32].
Tetraspanin protein CD151 is expressed by endothelial cells;
however, CD151-null mice had no vascular defects during normal
development or during neonatal oxygen induced retinopathy.
However, CD151-null mice had impaired angiogenesis in Matrigel
plug and corneal micropocket assays, and after tumor implanta-
tion. CD151-null mouse lung endothelial cells had normal
adhesion and proliferation, but marked alterations in migration,
spreading, invasion, Matrigel contraction, tube and cable forma-
tion, spheroid sprouting and connections between laminin-
binding integrins and other proteins were disrupted. CD151
modulates molecular organization of laminin-binding integrins,
thereby supporting secondary functions of endothelial cells, which
are needed for some types of pathologic angiogenesis [33]. CD151-
null mice had fewer lung metastases after iv injection of Lewis lung
carcinoma or B16F10 melanoma cells. Decreased tumor cell
residence in the lungs was evident 6–24 h after injection. Isolated
CD151-null mouse lung endothelial cells did not support B16F10
adhesion and trans-endothelial migration, B16F10-induced per-
meability, or B16F10 adhesion to extracellular matrix deposited by
CD151-null mouse lung endothelial cells. However, CD151
deletion did not affect metastatic foci or sc primary B16F10 tumor
size, tumor aggregation, tumor clearance from the blood, or tumor
induced immune cell activation and recruitment. Decreased
metastasis in CD151-null hosts may be due to impaired tumor-
endothelial interactions, and defects in lung endothelial cell
extracellular matrix production [34]. CD151 effects on pathologic
angiogenesis make it a potentially useful target for anticancertherapy. It is likely that formation of a CD151 complex with an
integrin is required for anigiogenesis, therefore and antibody or
other protein:protein disrupting agent could block the proangio-
genic effects of CD151. Agents which block CD151 proangiogenic
effects may be effective in combination with other anti-angiogenic
agents.
Thirty lung cancer lines were assessed for expression of
tetraspanins, CD9, CD63, CD81, CD82, CD151, and NAG-2. Among
these proteins, CD9 was broadly expressed in NSCLC lines, but
absent or highly reduced in SCLC lines. In cell motility assays, SCLC
OS3-R5 cells stably transfected with CD9 had reduced cell motility
on ﬁbronectin. Transient transfection of green ﬂuorescent protein
(GFP)-tagged CD9 into 3 SCLC lines resulted in less motile cells.
CD9 or GFP-CD9 associated with b1 integrins and distributed at the
tumor cell periphery and cell–cell contacts, suggesting that CD9
modiﬁes b1 integrin function to reduce motility. Low CD9
expression may contribute to SCLC invasion and metastasis [35].
The prognostic signiﬁcance of CD9in SCLC has not been explored.
2.8. NCAM/CD56
The value of several antibodies in SCLC diagnosis was assessed.
SCLC cases (20) and control cases (1 non-Hodgkin lymphoma, 3
NSCLC, 1 follicular reactive hyperplasia, and 5 chronic non-speciﬁc
inﬂammations) were stained using antibodies to NCAM (CD56),
MNF116, thyroid transcription factor 1 (TTF-1) and CD45. All SCLC
stained strongly positive for CD56 in 75–100% of tumor cells.
Eighteen of 20 cases were positive for TTF-1 and 16/20 were
positive for MNF116 in tumor cells. Control cases comprising
lymphoid cells were positive for CD45, and all SCLC were negative.
CD56, along with markers for cytokeratins – TTF-1, and CD45 – are
useful in SCLC diagnosis and may help conﬁrm the diagnosis in
equivocal cases [36]. CD56 is expressed on SCLC, neuroblastoma,
rhabdomyosarcoma, brain tumors, multiple myeloma and acute
myeloid leukemia. High NCAM expression is required for antibody-
based immunotherapies. The NCAM-targeted antibody-drug con-
jugate IMGN901 (lorvotuzumab mertansine) is in Phase II clinical
trial for ﬁrst-line treatment of SCLC. The trial evaluates IMGN901
used together with etoposide/carboplatin [37].
2.9. IGF-1R
The IGF-1R pathway is frequently up-regulated in SCLC, and is
associated with apoptosis inhibition and proliferation stimulation
through downstream signaling pathways including PI3K-Akt and
MAPK. OSI-906, a small molecule IGF-1R inhibitor and insulin
receptor inhibitor, was assessed in 19 SCLC lines. About 33% of lines
were sensitive to OSI-906 (IC50 < 1 mM). IGF-1R, IR, IGF-1, IGF-2,
IGFBP3, and IGFBP6 expression did not correlate with sensitivity to
OSI-906. OSI-906 sensitive lines had lower baseline phospho-ERK
relative to resistant lines. OSI-906 exposure resulted in a
concentration-dependent decrease in phospho-IGF-1R and phos-
pho-Akt in sensitive and resistant lines, but induced cell cycle
arrest and apoptosis only in sensitive lines. OSI-906 was assessed
in the NCI-H187 xenograft and two SCLC patient xenografts. OSI-
906 treatment resulted in 50% tumor growth inhibition in NCI-
H187 and 30% inhibition in the primary patient xenograft models.
IGF-1R inhibitors may be useful therapies for a SCLC subset
perhaps with low pretreatment phospho-ERK [38].
2.10. Fibroblast growth factor receptors
The ﬁbroblast growth factor/ﬁbroblast growth factor receptor
(FGF/FGFR) signaling pathway is fundamental in embryogenesis,
adult tissue homeostasis, and wound healing. FGF/FGFR oncogenic
mutations or ampliﬁcations occur in malignancies and promote
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resistance, supporting a rationale for anti-FGF/FGFR agent
development [39]. FGF pathway inhibitor development is compli-
cated because the FGF inhibitor must block the activity of multiple
mitogenic FGF ligands but spare the metabolic hormone FGFs (FGF-
19, FGF-21 and FGF-23). The engineered soluble FGF receptor 1 Fc
fusion protein, FP-1039 binds tightly to the mitogenic FGFs,
inhibits FGF-stimulated cell proliferation, blocks FGF- and VEGF-
induced angiogenesis, and inhibits tumor growth. FP-1039
antitumor activity correlated with FGF2, FGF18, FGFR1c, FGFR3c
RNA, and ETV4. FGF pathway genetic aberration models, including
FGFR1-ampliﬁed lung cancer and FGFR2-mutated endometrial
cancer, are very sensitive to FP-1039 antitumor activity. FP-1039
does not bind the hormonal FGFs. By selectively blocking non-
hormonal FGFs, FP-1039 has antitumor activity without the
toxicities associated with other FGF pathway inhibitors [40]. SCLC
lines have ampliﬁcation the FGFR1 gene. FGFR1 ampliﬁcation does
not always predict for the activity of the FGFR inhibitor PD173074.
The data from seven FGFR1-ampliﬁed SCLC cells suggested that not
all FGFR1-ampliﬁed SCLC tumors are dependent on FGFR1 activity
[41]. FGFR pathway inhibition remains an active area of
investigation in SCLC and other tumors in which this pathway is
dysregulated.
2.11. Transcription factors
2.11.1. MYC
MYC family DNA ampliﬁcation was present in 16/44 (36%) SCLC
lines established from previously treated patients compared to 7/
52 (11%) SCLC lines established from untreated patients. MYC DNA
ampliﬁcation is associated shorter patient survival [4]. The
apoptosis related gene caspase 8 is frequently silenced in SCLC
and SCLC lines usually, but not always, by aberrant promoter
methylation. In 34 SCLC lines (12 MYC ampliﬁed), caspase 8 gene
expression was lost in 79%, both mRNA and protein. MYC
ampliﬁcation was present in 45% of SCLC lines, which had lost
caspase 8 expression, but in none of the caspase 8 positive lines.
There has not been a formal study to assess whether Myc
ampliﬁed; caspase 8 negative tumors form a sub-class in response
to initial chemotherapy. There was also a high rate of loss of
expression of CASP10, DR5, FAS and FASL in SCLC. The loss of
expression of proapoptotic components was higher in MYC
ampliﬁed SCLC lines and these lines were completely TRAIL
resistant [42]. Array comparative genomic hybridization (aCGH)
karyotype analysis of 33 SCLC tumors and 13 SCLC lines showed
that SCLC tumor and line karyotypes were highly aberrant with
high copy number gains detected in SCLC tumors and lines in
cytogenetic bands encoding JAK2, FGFR1 and MYC family
members. The copy number of these genes often exceeded 100,
suggesting they represent driver alterations and drug targets in
SCLC. In SCLC tumors recurrent copy number alterations were
observed in 203 genes. The aCGH proﬁle of SCLC lines and clinical
SCLC specimens were similar [43].
Despite the discovery of an increasing number of MYC target
genes, identiﬁcation of MYC target core sets corresponding to
speciﬁc cellular outcomes has proved elusive. MYC is a transcrip-
tional ampliﬁer, increasing the transcription of genes that are
switched on in tumor cells, lymphocytes and stem cells. The
positive transcription elongation factor b (P-TEFb), which phos-
phorylates RNA Pol II and enables RNA transcript elongation, was
present at promoters bound by MYC. In proliferating B cells, MYC
preferentially binds to genes at which RNA Pol II is bound prior to
stimulation of proliferation. MYC is involved in the release of
paused RNA Pol II at transcriptional start sites. MYC effects are
broad and cell-type-speciﬁc because MYC ampliﬁes existing
genetic outputs. The c-Myc HLH-b ZIP protein is implicated inphysiological and pathological growth, proliferation, apoptosis,
metabolism, and differentiation via regulation of numerous target
genes. Myc target expression and function was observed in a model
where Myc was temporally and physiologically regulated, the
transcriptomes and the Myc genome-wide distribution, RNA Pol II,
and chromatin modiﬁcations were compared during lymphocyte
activation and in ES cells. The analysis showed that Myc does not
initiate gene activity; it ampliﬁes gene activity acting at active
genes [44]. In tumor cells expressing high c-Myc, Myc binds in
promoter regions of active genes and causes transcriptional
ampliﬁcation, producing increased transcripts from active genes
[45]. Myc has an important role in the regulation of cancer
metabolism. HIF1a inﬂuences metabolism via glycolysis up-
regulation and respiration suppression. Deregulated Myc and
HIF1a provide metabolic advantages to proliferating cancer cells
contributing to the Warburg effect. Myc overexpression stabilizes
HIF1a under normoxic conditions and enhances HIF1a accumula-
tion under hypoxic conditions [46]. c-MYC regulates radiation
tolerance through CHK1 and CHK2 checkpoint kinase transcrip-
tional ampliﬁcation through binding to the CHK1 and CHK2
promoters. c-MYC overexpression in cancer stem cells leads to
increased expression of CHK1 and CHK2 and subsequent activation
of the DNA-damage-checkpoint response resulting in radio-
resistance. CHK1 and CHK2 expression loss reverses radioresis-
tance in cancer stem cells. The c-MYC-CHK1/CHK2 axis is involved
in regulating DNA-damage-checkpoint responses and stem cell
characteristics [47]. In the clinic, CHK inhibitors are expected to be
useful in combination with radiation and with certain chemother-
apeutic agents.
Direct therapeutic targeting of MYC protein remains difﬁcult.
The Myc promoter contains a guanine-rich sequence (PU27)
capable of forming quadruplex (four-stranded) DNA, which may
negatively regulate myc transcription. Exposure of Myc over-
expressing cells to an oligonucleotide encoding the genomic PU27
sequence induced cell cycle arrest and death. PU27 is cell
permeable, stable in serum and has no effect on normal cells.
Suppression of Myc expression by PU27 caused DNA damage, cell
and mitochondrial swelling, and membrane permeability charac-
teristic of ischemic death [48]. Pharmacologically interfering with
the bromodomain and extraterminal (BET) proteins depletes
MYCN in cells resulting in cytotoxicity [49]. The bromodomain
reader protein family has a role in translating histone modiﬁca-
tions with transcriptional consequences; thus, bromodomain
proteins are potential therapeutic targets [50]. A combined
genomic and pharmacological (267 compounds) screen was
conducted in 44 SCLC lines in an attempt to identify SCLC-targeted
compounds. Aurora kinase inhibitors were effective in MYC-
ampliﬁed SCLC lines. Aurora kinase inhibition led to G2/M-arrest,
inactivation of PI3-kinase, and induction of apoptosis [41]. In early
clinical trials, a single agent Aurora kinase inhibitor produced a 21%
response rate (10/47 PRs) in refractory extensive SCLC [51].
R-enolase is a bifunctional gene encoding a glycolytic enzyme
and a DNA binding protein, c-myc binding protein (MBP-1). MBP-1
binds the c-myc promoter and down-regulates c-myc transcrip-
tion. R-enolase gene products have functions in glucose metabo-
lism and growth regulation. Serum neuron-speciﬁc enolase (NSE)
may be a SCLC prognostic factor. A prospective evaluation to assess
the prognostic signiﬁcance of pretreatment NSE and treatment-
induced minimum NSE in SCLC included two Phase III trials [71
extensive stage SCLC and 50 limited stage SCLC]. Both trials
included treatment with 4–6 cycles of etoposide and cisplatin.
Pretreatment NSE and treatment-induced minimum NSE values
were independent predictors of time to progression and survival in
multivariate analysis. Pretreatment NSE inversely correlated with
time to progression and survival [52]. R-enolase and MBP-1
expression was studied in low (1 nM), physiological (5 mM), or
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proliferation and lactate production were determined. At all
glucose concentrations, cells had an initial increase in MBP-1, a
decrease in myc transcript and decreased proliferation. Cells
grown in low glucose maintained MBP-1 for 48 h, resulting in
lower proliferation. Physiologic or high glucose exposure resulted
in decreased MBP-1, increased cellular proliferation and lactate
production. Myc returned to control levels as MBP-1 decreased;
thus, both R-enolase and MBP-1 suppressed c-myc making up-
regulation of these proteins potential strategies to limit myc
activity [53].
2.12. Other transcription factors
Nuclear transcription factor PAX5 protein expression is strong
in SCLC (11/12), and was not detected in NSCLC (13), mesothelioma
(7), esophageal (6) and head and neck cancer cell lines (12). PAX8
and PAX3 are non-detectable in SCLC cell lines; however, PAX8 was
expressed in NSCLC cell lines (13/13). In neuroendocrine tumor
samples, PAX5 expression frequency and intensity increased from
pulmonary carcinoid (9%, moderate and strong, n = 44), to large-
cell neuroendocrine carcinoma (LCNC, 27%, n = 11) to SCLC (33%,
n = 76). No PAX5 gene translocations were found by FISH, but there
was polyploidy in some SCLC tumors (6/37). PAX5 regulates the c-
Met transcription. Phospho-c-Met and PAX5 localized to the same
intra-nuclear compartment in hepatocyte growth factor treated
SCLC cells. PAX5 knockdown decreased the viability of SCLC cells
[54]. Paxillin is a downstream c-Met target which when activated
enhances cell motility and metastasis. Expression patterns of
PAX5, paxillin, c-Met, and phospho-c-Met in pulmonary neuroen-
docrine tumors including 38 typical carcinoids, 6 atypical
carcinoids, 34 SCLC, and 11 large cell neuroendocrine carcinomas
were studied by immunohistochemistry. These 4 tumor types
express c-Met, phospho-c-Met and paxillin. PAX5 was frequently
expressed in atypical carcinoids, SCLC, and large cell neuroendo-
crine carcinomas but rarely in typical carcinoids. PAX5 and c-Met
or phospho-c-Met were present in the atypical carcinoids, SCLC,
and large cell neuroendocrine carcinomas [55]. Clinical trials of c-
Met inhibitors are underway in non-small cell lung cancer; and a
phase I clinical trial of tivantinib (ARQ197) plus topotecan is
underway in SCLC [56].
To determine STAT3, P-STAT3, and VEGF-C expression in SCLC,
immuno-histochemical methods were applied to 128 SCLC and 40
adjacent normal tissue specimens. The STAT3, P-STAT3, and VEGF-
C expression was higher in SCLC than in normal tissue. Pairwise
comparisons showed positive correlations with lymph node
metastasis, clinical stage, tumor size, and overall survival [57].
SCLC have decreased active PI3-kinase and Ras/MAP/ERK kinase
pathways but increased E2F1-regulated factors including EZH2,
thymidylate synthase, apoptosis mediators and DNA repair
proteins than NSCLC and PARP1 was highly expressed in SCLC.
SCLC growth was inhibited by PARP1 and EZH2 knockdown [58].
The knockdown of PARP1 and EZH2 abrogated SCLC growth [59].
Exposure of SCLC lines to hydroxamate histone deacetylase
inhibitors depleted EZH2, decreased trimethylated and dimethy-
lated H3K27 and homeobox domain containing HOXA9 and MEIS1
transcription factors depletion [60]. EZH2, SUZ12, and EED, induce
trimethylation of lysine 27 on histone H3, regulate HOX gene
expression, and promote neoplastic cell proliferation and
aggressiveness [61]. The human achaete-scute homolog 1
(hASH1) and EZH2 genes are upregulated in SCLC compared to
normal tissues. The regulatory regions from the hASH1- and
EZH2-promoter regions alone and in combination were tested as
suicide SCLC gene therapy. Two hASH1-promoter regions
comprising 0.3 and 0.7 kb immediately upstream of the tran-
scription start site induced reporter gene activity (7-foldSV40-promoter activity) in hASH1-positive SCLC and in 2
hASH1-negative SCLC lines. Therapeutic potential, the 0.7 kb
hASH1 proximal-promoter region was evaluated for cytotoxicity
in a suicide gene assay. The construct induced SCLC cytotoxicity. A
1.1 kb EZH2-promoter region was evaluated by reporter and
suicide gene assays. The EZH2 promoter potently induced
reporter gene activity in SCLC. However, in the suicide gene
assay both control and SCLC cells demonstrated sensitivity
indicating lack of promoter speciﬁcity. The modiﬁed hASH1EZH2
promoter was a more promising transcriptional regulator for SCLC
gene therapy [62]. In the epigenetics area, there is currently an
active Phase 1 clinical trial in SCLC examining the efﬁcacy of
cisplatin and eptoposide in combination with the histone
deacetylase inhibitor, belinostat [63].
3. Metabolism
Many cancers are dependent on aerobic glycolysis for ATP
production, a metabolic proﬁle described as the Warburg effect.
The dependence on glycolysis requires glucose transporter 1
(GLUT1) induction, thus, compounds targeting glucose uptake
through GLUT1 may be of therapeutic beneﬁt. Treatment with
GLUT1-targeted agents may impede glucose uptake with limited
toxicity to normal tissue [64]. Cancer stem cell metabolism may
differ from their progeny. When oxygen consumption rate,
extracellular acidiﬁcation rate, intracellular ATP, glucose uptake,
lactate production, PKM1 and PKM2 expression, radiation sensi-
tivity, and cell cycle duration of cancer stem cells and their progeny
was determined, cancer stem cells and progenitor cells were less
glycolytic than differentiated progeny cells. Cancer stem cells
consumed less glucose and produced less lactate while maintain-
ing higher ATP than their differentiated progeny. Compared with
differentiated cells, cancer stem cells were radio-resistant, and this
correlated with a higher mitochondrial reserve capacity. Cancer
stem cells may rely mainly on oxidative phosphorylation;
however, if challenged, can use additional metabolic pathways
[65]. Thus, cancer stem cells may be less susceptible to metabolic
inhibitors directed toward glycolytic targets than are their
progeny. Elevated glucose consumption may be a necessary
component of carcinogenesis. Glycolysis may be elevated in
cancer because it produces acid, which provides an evolutionary
advantage to cancer cells compared with normal parenchyma [66].
Mitochondrial cytochrome c release and Smac/DIABLO expres-
sion are implicated in apoptosis in response to cell stress. Smac
promotes cytochrome c-induced caspase activation by sequester-
ing the inhibitor of apoptosis protein family of potent caspase
suppressors. The mechanism by which ﬁbroblast growth factor 2
(FGF-2) protects SCLC from etoposide-induced cell death involves
inhibition of Smac release but not cytochrome c release by a MEK-
dependent process that correlates with increased XIAP and cellular
IAP-1 expression and is mediated through translational regulation.
Exogenous XIAP expression can inhibit caspase 9 activation, Smac
release, and cell death induced by etoposide. Prevention of FGF-2-
promoted increase in functional IAPs by RNA interference or cell-
permeant Smac amino-terminal peptide can block FGF-2-induced
protection. FGF-2 can protect SCLC from chemotherapeutic drugs
by modulating IAP via posttranscriptional regulation, providing a
mechanism for post mitochondrial survival signaling by the MEK/
mitogen-activated protein kinase pathway [67].
There is a need for models that preserve cancer stem cell
populations, and 3D tumor-stromal interactions [68].
3.1. Bcl-2
Bcl-2, a central cell survival regulator and a key apoptotic
resistance gene, is overexpressed in most SCLC and contributes to
B.A. Teicher / Biochemical Pharmacology 87 (2014) 211–219 217malignant transformation and therapeutic resistance. Primary
SCLC xenografts and cell line-based xenografts were used to
evaluate the novel Bcl-2 inhibitor, ABT-737. ABT-737 induced
regressions in tumors derived from some SCLC lines. One of 3
primary SCLC xenografts showed growth inhibition with ABT-737.
The combination of etoposide and ABT-737 in primary xenografts
resulted in decreases in tumor growth. To identify ABT-737
resistance factors, resistant sublines were developed. Acquired
resistance was associated with decreased Bcl-2 expression, and
Bcl-2 proapoptotic partners, Bax and Bim, and Bcl-2:Bim hetero-
dimers. Expression proﬁling showed consistent changes in 85
genes [69]. ABT-737 may induce tumor cell autophagy. SCLC
combination treatment with ABT-737 and chloroquine decreased
viability and increased caspase-3 activation compared with either
single agent. However, ABT-737 induced autophagy and beclin-1
knockdown diminished ABT-737 efﬁcacy, suggesting that chloro-
quine effects were nonspeciﬁc or induction of autophagy is
required for the ABT-737 and chloroquine combined effect. In
SCLC, ABT-737 and chloroquine administration down-regulated
Mcl-1 and upregulated NOXA which may promote apoptosis.
Treatment of NCI-H209 tumor bearing mice showed that chloro-
quine could enhance ABT-737-mediated tumor growth inhibition,
but did not alter response of three primary patient-derived
xenografts to ABT-737 [70].
Navitoclax (ABT-263), a small molecule Bcl-2 and Bcl-xL
inhibitor, has activity in SCLC models. When navitoclax was
evaluated in phase II in recurrent and metastatic SCLC patients, the
response rate was low, but consistent with prior observations in
primary SCLC xenografts [71]. The most common navitoclax
toxicity in patients (39) was thrombocytopenia (grade 3–4 in 41%
of pts). Partial response was observed in a single pt (2.6%) and
stable disease in 9 pts (23%). Median PFS was 1.5 months and
median OS 3.2 months. A correlation between plasma pro-gastrin
releasing peptide and tumor Bcl-2 copy number (R = 0.93) was
conﬁrmed. Baseline cytokeratin 19 fragment antigen 21–1,
neuron-speciﬁc enolase, pro-GRP and circulating tumor cell
number correlated with clinical beneﬁt [72].
3.2. Stem-like characteristics
Side population (SP) cells, identiﬁed by efﬂux of Hoechst dye,
are present in virtually all normal and malignant tissues. The
relationship between SP cells, drug resistance and cancer stem
cells is poorly understood. The highly aggressive nature of SCLC
suggests that this disease may have a high stem cell fraction. SCLC
SP cells are highly enriched in tumorigenic cells and are
characterized by a stem cell associated gene expression signature
[73]. SP cells have high proliferative capacity in vitro, efﬁcient self-
renewal and reduced cell surface expression of differentiation
markers, CD56 and CD90. Fifty NCI-H146 or NCI-H526 SCLC SP cells
formed tumors in mice, while non-SP cells formed fewer and
slower-growing tumors. SCLC SP cells over-expressed genes
associated with cancer stem cells and drug resistance: CD133,
ABCG2, FGF1, IGF1, MYC, SOX1/2, WNT1, angiogenesis genes, and
notch and hedgehog pathways [74]. Cancer may be viewed as
aberrant organogenesis in which progenitor/stem cells escape
dependence on niche signaling through mutation in genes such as
Ptch or through activation of progenitor cell pathways. Normally
the airway epithelial uses the hedgehog pathway to repopulate
after injury. Activation of the hedgehog pathway has been studied
in a mouse SCLC model (mSCLC) in which Rb1 and Trp53 were
deleted in the lung epithelium. mSCLC expressed hedgehog
pathway components in vivo and in culture. Crossing a constitu-
tively active allele of the hedgehog pathway member Smoothened
(Smo) into Rb1-Trp53 conditional mutant mice led to an increase in
the size and number of lung nodules per mouse while Smo deletionresulted in fewer and smaller nodules. Smo and Gli1 inhibitors
blocked proliferation and increased death in mSCLC. In vivo, Smo
inhibition following cisplatin and etoposide treatment was
effective in preventing SCLC xenograft regrowth, suggesting that
hedgehog pathway inhibitors may be useful therapies [75].
Hedgehog acyltransferase (Hhat)-mediated palmitoylation, a
modiﬁcation critical for hedgehog signaling, is a target for Shh
pathway inhibition. In cells, Hhat inhibitors blocked hedgehog
palmitoylation and inhibited autocrine and paracrine hedgehog
signaling [76].
SCLC is characterized by high levels of SOX2, SOX4, and SOX11
along with the SOX4-speciﬁc gene expression signature. The HMG
box transcription factor SOX4 involved in neuronal development is
ampliﬁed and overexpressed in SCLC and may be a driver oncogene
[77]. CD44highCD90+ cells from primary SCLC lines had mesen-
chymal morphology, increased expression of mesenchymal
markers N-cadherin and vimentin, increased mRNA levels of the
embryonic stem cell related genes Nanog and Oct4 and increased
resistance to irradiation compared to other sub-populations,
suggesting the CD44highCD90+ population a good candidate for
the SCLC cancer stem cells [78].
4. Conclusion
Drug discovery is exceptionally challenging for SCLC tumors.
Genetic and epigenetic changes including gene mutations, dele-
tions, ampliﬁcations, translocations and methylation induced gene
silencing found in SCLC are frequent in SCLC cell lines; however,
questions regarding the genomic stability, lack of differentiation
and absence of stromal–vascular–inﬂammatory cell compart-
ments are issues [79]. Since biopsies are rare in SCLC, SCLC cell lines
remain the main tool for SCLC biological characterization and
translational research. The lack of SCLC progenitor cell type
knowledge prevents identiﬁcation of SCLC gene expression
changes compared to the most appropriate normal cell [80].
Several of the potential cell surface targets in SCLC are GPCRs
including the bradykinin receptor, CXCR4, the 3 bombesin
receptors and the vasopressin receptor. GPCR stimulation is
maintained by autocrine and paracrine loops of neuropeptides
with well-deﬁned physiologic actions. The tumor microenviron-
ment may provide GPCR stimulants, such as chemokines. Small
molecule and peptide CXCR4 inhibitors are under investigation in
SCLC and other cancers. Multiple neuropeptide autocrine systems
are active in SCLC. Neuropeptide derivatives based on the
substance P exhibit broad speciﬁcity for neuropeptide receptors.
In addition, SCLC clinical trials have targeted chemokine receptors,
in particular CXCR4, the CXCL12 (SDF-1) receptor. The CXCR4
antagonist, plerixafor, is approved for the mobilization of
hematopoietic stem cells for autologous transplantation [15]. By
analogy, this strategy may be able to mobilize SCLC cells into
circulation making them more susceptible to cytotoxic chemo-
therapy. Several of the targets discussed have been studied earlier
in SCLC and may be worth re-visiting with modern approaches.
Targets such as Myc have been known in SCLC for some time but
remain difﬁcult to approach therapeutically. Other targets have
only recently become of interest. Recurrent SCLC is among the
most recalcitrant cancers such that additional drug development
efforts focused on achieving clinical beneﬁt are a high priority.
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